RichardSamuelFinnMD
Oncology • Santa Monica, CAAssistant Professor, Medicine, UCLA School of Medicine
Are you Dr. Finn?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 90 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2020 Santa Monica Blvd Ste 600
Santa Monica, CA 90404Phone+1 310-829-5471Fax+1 310-829-6192- Is this information wrong?
Summary
- Dr. Richard Finn, MD is an oncologist in Santa Monica, California. He is currently licensed to practice medicine in California. He is affiliated with UCLA Medical Center-Santa Monica and is an Assistant Professor at UCLA School of Medicine.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2000 - 2003- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1997 - 2000
Keck School of Medicine of the University of Southern CaliforniaClass of 1997
Certifications & Licensure
CA State Medical License 1999 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma Start of enrollment: 2009 Jun 01
- Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer Start of enrollment: 2009 Feb 01
- Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery Start of enrollment: 2011 Jan 13
- Join now to see all
Publications & Presentations
PubMed
- Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma.Josep M Llovet, Roser Pinyol, Mark Yarchoan, Amit G Singal, Thomas U Marron, Myron Schwartz, Eli Pikarsky, Masatoshi Kudo, Richard S Finn> ;Nature Reviews. Clinical Oncology. 2024 Apr 1
- 1 citationsRegorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial.Hyung-Don Kim, Seyoung Jung, Ho Yeong Lim, Baek-Yeol Ryoo, Min-Hee Ryu, Samuel Chuah, Hong Jae Chon, Beodeul Kang, Jung Yong Hong, Han Chu Lee, Deok-Bog Moon, Ki-Hun K...> ;Nature Medicine. 2024 Mar 1
- Author Correction: Hepatocellular carcinoma.Llovet, J., Villanueva, A., Pikarsky, E., Lencioni, R., Koike, K., Zucman-Rossi, J., Kelley, R., Singal, A., Roayaie, S., Finn, R.> ;Nature Reviews. Disease Primers. 2024 Feb 12
- Join now to see all
Authored Content
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular CarcinomaMay 2020
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular CarcinomaMay 2020
- Palbociclib plus Endocrine Therapy in Older Women with HR+/HER2– Advanced Breast Cancer: A Pooled Analysis of Randomised PALOMA Clinical StudiesAugust 2018
Press Mentions
Novartis Announces Tislelizumab Demonstrated Efficacy and Tolerability in First-Line Advanced Liver Cancer in Phase III TrialSeptember 10th, 2022- PALOMA-2: No Overall Survival Benefit Reported with Palbociclib/Letrozole in Advanced Breast CancerJuly 26th, 2022
- New Data on Emerging Treatments for Liver Cancer Raise Hope for Advanced Disease PatientsAugust 27th, 2020
- Join now to see all
Hospital Affiliations
UCLA Medical Center-Santa MonicaSanta Monica, California
